116 267

Cited 4 times in

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

Authors
 Sung-Bae Kim  ;  Jae Hong Seo  ;  Jin-Hee Ahn  ;  Tae-Yong Kim  ;  Seok Yun Kang  ;  Joohyuk Sohn  ;  Yaewon Yang  ;  Kyong Hwa Park  ;  Yong Wha Moon  ;  Seungtaek Lim  ;  Myoung Joo Kang  ;  Koung Eun Yoon  ;  Hyun Ju Cho  ;  Keun Seok Lee 
Citation
 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.13 : 17588359211061989, 2021-12 
Journal Title
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
ISSN
 1758-8340 
Issue Date
2021-12
Keywords
DHP107 ; HER2-negative ; first-line ; metastatic breast cancer ; oral paclitaxel
Abstract
Background: Standard intravenous (IV) paclitaxel is associated with hypersensitivity/toxicity. Alternative IV formulations have improved tolerability but still require frequent hospital visits and IV infusion. DHP107 is a novel oral formulation of paclitaxel that is approved in South Korea for the treatment of gastric cancer.

Methods: This multicenter, phase II study using a Simon's two-stage design investigated the efficacy and safety of DHP107 200 mg/m2 administered orally twice daily on days 1, 8, and 15 every 4 weeks for the first-line treatment of recurrent or metastatic HER2-negative breast cancer.

Results: Thirty-six patients were enrolled and 31 were assessable for efficacy. Patient median age was 57 years (range = 34-81) and 11 (31%) had triple-negative disease. A median of seven cycles (range = 1-28) of DHP107 was administered. Objective response rate was 55% (17 patients), all partial responses, according to the investigator's decision and independent central review (ICR), and 44% (4/9 patients) in those with triple-negative disease. Disease control rate (partial response and stable disease) was 74% (23 patients) according to the investigator's decision and ICR. In the intention-to-treat (ITT) population of all enrolled participants, the objective response rate was 50% (18/36 patients). Median progression-free survival was 8.9 months [95% confidence interval [CI]: 5.2-12.3) and median time to treatment failure was 8.0 months (95% CI: 4.2-10.0). DHP107 had an acceptable toxicity profile. All patients experienced treatment-emergent adverse events; the most common adverse events were decreased neutrophil count (81% all grades and 78% grade ⩾ 3) followed by peripheral sensory neuropathy (61% all grades and 8% grade 3). However, there was no febrile neutropenia or sepsis.

Conclusion: DHP107 showed promising efficacy and acceptable tolerability in this phase II study and is currently being investigated in the OPTIMAL phase III study (NCT03315364).

Trial registration: This trial was registered with ClinicalTrials.gov identifier: NCT03315364.
Files in This Item:
T202126222.pdf Download
DOI
10.1177/17588359211061989
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190636
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links